IS ONCOLYTIC VIROTHERAPY A VIABLE PLATFORM FOR GLIOMA TREATMENT?
Main Article Content
Gliomas are devastating cancers of the nervous system with poor prognosis.
Their aggressiveness produces a mortality rate rarely seen with other malig-nant tumours and the lack of effective treatment has left very few options. On-colytic viruses, with their long history of experimentation, have been deemed
to be a key player in the future treatment of gliomas. This review will focus
on the two main contenders, adenovirus and herpes simplex virus, for glioma
treatment and discuss how far the field has come since its conception. The
concept of each vector and the rationales behind their use will be contrasted
before discussing the future of the field. Data was located by accessing the
MEDLINE database using the PubMed search system. Data was selected on
the basis of the insight its information provided as well as on the dependabil -ity of the experimental method used.
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.